Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tackling gaps in developing life-changing treatments for dementia.
Mauricio R, Benn C, Davis J, Dawson G, Dawson LA, Evans A, Fox N, Gallacher J, Hutton M, Isaac J, Jones DNC, Jones L, Lalli G, Libri V, Lovestone S, Moody C, Noble W, Perry H, Pickett J, Reynolds D, Ritchie C, Rohrer JD, Routledge C, Rowe J, Snyder H, Spires-Jones T, Swartz J, Truyen L, Whiting P; Therapeutics for Dementia Consortium. Mauricio R, et al. Among authors: dawson la, dawson g. Alzheimers Dement (N Y). 2019 Jun 24;5:241-253. doi: 10.1016/j.trci.2019.05.001. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31297438 Free PMC article. Review.
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.
Ward SE, Beswick P, Calcinaghi N, Dawson LA, Gartlon J, Graziani F, Jones DN, Lacroix L, Selina Mok MH, Oliosi B, Pardoe J, Starr K, Woolley ML, Harries MH. Ward SE, et al. Among authors: dawson la. Br J Pharmacol. 2017 Mar;174(5):370-385. doi: 10.1111/bph.13696. Epub 2017 Jan 31. Br J Pharmacol. 2017. PMID: 28009436 Free PMC article.
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM. Medhurst AD, et al. Among authors: dawson la. J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45. doi: 10.1124/jpet.107.120311. Epub 2007 Feb 27. J Pharmacol Exp Ther. 2007. PMID: 17327487
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW. Dawson LA, et al. Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30. Eur J Pharmacol. 2010. PMID: 19879867
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. Dawson LA, et al. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. doi: 10.1038/sj.npp.1301549. Epub 2007 Aug 29. Neuropsychopharmacology. 2008. PMID: 17728699
385 results